Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained Settings
Rupak Shivakoti(Johns Hopkins University), Amita Gupta(Johns Hopkins University), Selvamuthu Poongulali(YR Gaitonde Centre for AIDS Research and Education), Thomas Campbell(University of Colorado Anschutz Medical Campus), Richard D. Semba(Johns Hopkins University), Wadzanai Samaneka(University of Zimbabwe), Ashwin Balagopal(Johns Hopkins University), Srikanth Tripathy(Indian Council of Medical Research), Wei-Teng Yang(Johns Hopkins University), Nikhil Gupte(Johns Hopkins University), Patcharaphan Sugandhavesa(Chiang Mai University), Robert C. Bollinger(Johns Hopkins University), Sima Berendes(Johns Hopkins University), Sandra Wagner Cardoso(Instituto Evandro Chagas), Cecilia Kanyama, Noluthando Mwelase(University of the Witwatersrand), Cynthia Riviere(Hôpital Necker-Enfants Malades), Javier R. Lama(Asociación Civil Impacta Salud y Educación), Sandy Pillay(Durban University of Technology), Breno Santos(Hospital Nossa Senhora da Conceição)
Cited by 25
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
|New England Journal of Medicine|2021|557
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
|New England Journal of Medicine|2021|548